PCI, a leading global contract development and manufacturing organization (CDMO) specializing in biotherapies, has secured a strategic investment co-led by Bain Capital and Kohlberg, with significant reinvestment from Mubadala Investment Company. Partners Group will also maintain a minority investment in the company. The financial details of the transaction remain undisclosed.

Based in Philadelphia, PCI offers comprehensive drug development, manufacturing, and packaging services, enhancing clients' market entry and commercial success. With over 450 successful product launches in the past five years and more than 50 years in the pharmaceutical sector, PCI is committed to improving patient access and outcomes through innovative solutions.

The investment aims to accelerate PCI's growth, enhance customer service, and support clients in bringing transformative biopharmaceutical therapies to market. The company plans to pursue both organic and inorganic growth strategies, expanding its service offerings and geographic presence. Future investments will focus on increasing sterile fill-finish capabilities for injectables and specialized manufacturing, while also strengthening the U.S. pharmaceutical manufacturing infrastructure.

CEO Salim Haffar emphasized PCI's commitment to becoming a global CDMO through a robust growth strategy and superior customer experience. He expressed gratitude for the ongoing support from existing investors and welcomed Bain Capital's expertise in healthcare and life sciences to further enhance PCI's services.

Matt Jennings, Chairman of PCI and Operating Partner at Kohlberg, highlighted the successful collaboration between PCI's management and experienced investors, which has proven effective in driving growth. He welcomed Bain Capital as a new partner, aligning with PCI's ambitions for value creation.

Bain Capital's Devin O’Reilly noted PCI's innovative platform and reputation as a reliable partner for biopharma companies, emphasizing the importance of ensuring critical therapies reach patients efficiently. He, along with partners Andrew Kaplan and Christina Dix, expressed excitement about leveraging their industry expertise to support PCI's mission of advancing pharmaceutical services.

Kohlberg's Chris Anderson acknowledged PCI's transformation into a leading global CDMO over the past five years, positioning it in rapidly growing markets. He expressed enthusiasm for the partnership with Bain Capital to enhance PCI's capabilities and growth trajectory.

Mina Hamoodi from Mubadala reiterated the firm's confidence in PCI's leadership and long-term potential, expressing excitement about collaborating with Bain and Kohlberg as PCI embarks on its next growth phase.

Overall, this strategic investment marks a significant step for PCI, reinforcing its position in the biopharmaceutical sector and enabling it to meet the evolving demands of its clients while improving patient outcomes.